期刊
GASTROENTEROLOGY CLINICS OF NORTH AMERICA
卷 46, 期 1, 页码 91-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.gtc.2016.09.014
关键词
Intestinal microbiota; Functional bowel disorders; Irritable bowel syndrome
资金
- Nestle
- Salix Pharmaceuticals
- Danisco
- Prometheus Therapeutics and Diagnostics
- Ironwood
- Takeda
- Procter Gamble
Emerging data from epidemiologic, microbiome, and physiology research in patients with functional bowel disorders (FBDs) provide evidence for a linkage between alterations in the intestinal microbiota and FBDs. However, currently most of the data is based on association studies, and the causality role of the microbiota in these disorders is not established. Growing evidence for compositional changes and the increasing recognition of the association between the intestinal microbiota and gut-brain functions that are relevant to the pathophysiology and/or clinical symptoms of FBDs have led to increased interest in manipulating the intestinal microbiota for the treatment of these disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据